AstraZeneca is acquiring Icosavax, which has technology well-suited for multivalent vaccines. Icosavax’s pipeline includes a Phase 3-ready program that protects against two pathogens that cause severe respiratory infections in older adults. By FRANK VINLUAN AstraZeneca is already in the respiratory syncytial virus market with two products, including the drug Beyfortus, approved earlier this year. An M&A deal will give AstraZeneca an RSV vaccine candidate based on technology that could help the company compete where new vaccines are going. AstraZeneca is acquiring clinical-stage Icosavax for $800 million up front, the pharmaceutical giant announced Tuesday. Under the deal terms, AstraZeneca will pay $15 for each Icosavax share, which is a nearly 43% premium to the stock’s closing price on Monday. AstraZeneca could pay an additional $5 per share depending on the progress of Icosavax’s vaccine candidates. That payout could bring the value of the deal to $1.1 billion. The vaccines of Seattle-based ...
Recently, CanSino Biologics’ adsorbed acellular (component) diphtheria-tetanus combination vaccine (hereinafter referred to as “Tdcp for adolescents and adults”) officially launched Phase I clinical trials and completed the enrollment of the first subject. Tdcp for adolescents and adults is suitable for people aged 6 years and above. It is a booster vaccine for adolescents and adults. This randomized, blinded, controlled phase I clinical trial will initially evaluate the safety and immunogenicity of the vaccine. Whooping cough, diphtheria and tetanus, also known as diphtheria, are serious diseases caused by bacteria. Since the protective effect of immunity triggered by the main antigen of pertussis gradually decreases after vaccination, the incidence and mortality of pertussis gradually increase in the post-vaccination population. The domestic market is in urgent need of a DPT vaccine with longer-lasting immune protection and higher safety. Major developed countries have included this vaccine in their regular vaccination plans, but there is ...
December 1, 2023 – CanSino Biologics Inc. (“CanSinoBIO” or “the Company”) kicked off its innovative Polio VLP Vaccine Cooperation that aims to eradicate polio worldwide today as representatives from The Bill & Melinda Gates Foundation (the foundation) visited the facility. Dr. Xuefeng Yu, Chairman and CEO, Dr. Shoubai Chao, Chief Operating Officer, Dr. Tao Zhu, Chief Scientific Officer, and Ms. Jing Wang, Chief Commercial Officer and representatives from CanSinoBIO gave warm welcome to the foundation delegation. Dr. Xuefeng Yu expressed his gratitude to the foundation for their support over the past years that enabled CanSinoBIO to play a vital role in the global polio eradication efforts. CanSinoBIO is committed to continuously focusing on this fight against the vaccine-preventable disease and make a greater impact on global public health. CanSinoBIO has been actively participating in the World Health Organization (the WHO) polio eradication strategy to eliminate the disease, and has been ...
Walvax Biotechnology Co., Ltd. (hereinafter referred to as the “Company”), in cooperation with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co. (hereinafter referred to as the “RQ3033 Vaccine” or the “Vaccine”) developed by the Company in cooperation with Fudan University and Shanghai Blue Magpie Bio-pharmaceutical Company Limited (hereinafter referred to as the “Shanghai Blue Magpie”), which was approved by the relevant state departments for inclusion in the Emergency Use Program after receiving a letter from the Vaccine Research and Development Task Force of the State Council’s Research and Development Group of the Joint Prevention and Joint Control Mechanism on December 1, 2023 The “Vaccine” was approved for emergency use by the relevant state departments. The RQ3033 vaccine is an iterative vaccine developed on the basis of the mRNA technology platform jointly established by the Company, Fudan University and Shanghai Blue Magpie, and on the basis of the first-generation vaccine, i.e., ...
Important Notice: Changchun BCHT Biotechnology Co. (hereinafter referred to as the “Company”) has recently received the Notice of Approval of Drug Clinical Trial from the State Drug Administration. 2, the freeze-dried human rabies vaccine (human diploid cells) subsequent clinical trials are uncertain, and there is a certain degree of uncertainty whether the commercial purpose can ultimately be achieved. Investors are kindly advised to make decisions with caution and pay attention to the prevention of investment risks. The relevant information is announced as follows: I. Main information of the Notice of Approval of Drug Clinical Trial Acceptance No.: CXSL2300615 Notification No.: 2023LP02456 Drug Name: Lyophilized Human Rabies Vaccine (Human Diploid Cells) Conclusion: Agree to carry out clinical trials for the prevention of rabies. Approval date: December 6, 2023 The freeze-dried human rabies vaccine (human diploid cell) approved by the Company this time is freeze-dried human rabies vaccine (MRC-5 cell). II. Introduction ...
By Tristan Manalac Pictured: GSK building in Poznan, Poland/iStock, Wirestock GSK CEO Emma Walmsley on Thursday touted the smooth launch of its respiratory syncytial virus vaccine Arexvy and its strong potential for growth in the coming years. In an interview with Reuters, Walmsley said the British biopharma is “delighted” with the progress it has made in the RSV vaccine race with Pfizer. “We are delighted with the start of our RSV vaccine,” Walmsley said, adding that the company expects Arexvy “will be more than £1 billion in its first year, (it) has lots of headroom for growth.” GSK is positioning Arexvy to be its next blockbuster asset. The U.S. launch of the vaccine has so far reached three million of the more than 80 million adults over 60 at risk from RSV, according to Walmsley. Arexvy became the first FDA-approved RSV shot in May 2023 and is authorized for use ...
The World Health Organization (WHO) has commissioned 16 ‘Vaccine Value Profiles (VVPs)’ to prioritise key endemic pathogens to accelerate vaccine development. The VVPs are a result of collaboration between several pathogen and vaccine experts.Led by the Product Development and Research (PDR) team in WHO’s immunisation, vaccines and biologicals department, the aim of the VVPs is to advance the development of vaccines for pathogens that pose the biggest threat to public health and socio-economic burden, particularly in low- and middle-income countries. The forthcoming supplement in the journal Vaccine will feature the VVPs of 16 pathogens with vaccines in late-stage clinical development to provide comprehensive summaries of critical evidence to provide guidance for vaccine funding, research initiatives, and clinical and policy development strategies. They will comprise state-of-the art, publicly available data and information that highlights the current understanding of anticipated vaccine development, the implementation of feasibility studies and the public health impact ...
Valneva’s chikungunya vaccine has been granted accelerated approval by the US Food and Drug Administration (FDA) for use in individuals ages 18 years and older who are at an increased risk of exposure to the mosquito-borne disease. The decision makes Ixchiq, which is administered as a single intramuscular injection, the world’s first licensed chikungunya vaccine. Chikungunya often causes sudden large outbreaks with high attack rates, affecting one-third to three-quarters of the population in areas where the virus is circulating. Infection leads to symptomatic disease in up to 97% of people after three to seven days following the mosquito bite, with clinical symptoms including fever, joint and muscle pain, headache, nausea and rash. “Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for older adults and individuals with underlying medical conditions,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. He added: ...
By Kate Goodwin Pictured: A researcher at work in a Novavax laboratory/Novavax, Patrick Siebert Combination vaccines are nothing new for the healthcare industry. Childhood vaccines, as well as a single shot for tetanus, diphtheria and pertussis for adults, have long been combined for ease of administration and increased compliance rates. Now, as vaccines for COVID-19 and, for older people, RSV and pneumococcal disease join the annual flu shot as routine care recommendations for adults, healthcare professionals are increasingly concerned over getting the word out, vaccine fatigue and logistical hurdles. Biopharma companies are betting there will be a market for vaccines that combine protection against two or more diseases in a single jab. Benefit to the Population “The data are pretty unequivocal that when there are combo vaccines available, people generally prefer [them],” said Andrea C. Love, an immunologist and microbiologist and founder of the Unbiased Science Podcast. Love pointed out ...
Novavax has announced that its updated COVID-19 vaccine, Nuvaxovid XBB.1.5, has been approved by the European Commission (EC) for active immunisation in individuals aged 12 and older. The decision follows a positive opinion for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). Developed to target the Omicron XBB sublineage, the updated vaccine prepares the body’s defences against COVID-19 and contains a version of the spike protein of the Omicron XBB.1.5 subvariant, as well as Matrix-M adjuvant to strengthen immune response. The approval was based on non-clinical data which showed that the vaccine induced functional immune responses against the COVID-19 variants XBB.1.5, XBB.1.16 and XBB.2.3. Additionally, the updated vaccine induced neutralising antibody responses to newly emerging subvariants of the SARS-CoV-2 virus, BA.2.86, EG.5.1, FL.1.5.1 and XBB.1.16.6, as well as strong CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. Based on previous recommendations by ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.